Literature DB >> 34154922

Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.

Sun H Peck1, Yian Khai Lau1, Jennifer L Kang1, Megan Lin1, Toren Arginteanu1, Dena R Matalon2, Justin R Bendigo1, Patricia O'Donnell3, Mark E Haskins3, Margret L Casal3, Lachlan J Smith4.   

Abstract

Mucopolysaccharidosis (MPS) VII is a lysosomal storage disorder characterized by deficient β-glucuronidase activity, leading to accumulation of incompletely degraded heparan, dermatan and chondroitin sulfate glycosaminoglycans. Patients with MPS VII exhibit progressive spinal deformity, which decreases quality of life. Previously, we demonstrated that MPS VII dogs exhibit impaired initiation of secondary ossification in the vertebrae and long bones. The objective of this study was to build on these findings and comprehensively characterize how vertebral bone disease manifests progressively in MPS VII dogs throughout postnatal growth. Vertebrae were collected postmortem from MPS VII and healthy control dogs at seven ages ranging from 9 to 365 days. Microcomputed tomography and histology were used to characterize bone properties in primary and secondary ossification centers. Serum was analyzed for bone turnover biomarkers. Results demonstrated that not only was secondary ossification delayed in MPS VII vertebrae, but that it progressed aberrantly and was markedly diminished even at 365 days-of-age. Within primary ossification centers, bone volume fraction and bone mineral density were significantly lower in MPS VII at 180 and 365 days-of-age. MPS VII growth plates exhibited significantly lower proliferative and hypertrophic zone cellularity at 90 days-of-age, while serum bone-specific alkaline phosphatase (BAP) was significantly lower in MPS VII dogs at 180 days-of-age. Overall, these findings establish that vertebral bone formation is significantly diminished in MPS VII dogs in both primary and secondary ossification centers during postnatal growth.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Canine; Growth plate; Lysosomal storage disease; Mucopolysaccharidosis; Spine

Mesh:

Year:  2021        PMID: 34154922      PMCID: PMC8289741          DOI: 10.1016/j.ymgme.2021.06.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.204


  38 in total

1.  Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII.

Authors:  Sun H Peck; John W Tobias; Eileen M Shore; Neil R Malhotra; Mark E Haskins; Margret L Casal; Lachlan J Smith
Journal:  Bone       Date:  2019-08-20       Impact factor: 4.398

2.  C-Type Natriuretic Peptide Restores Growth Impairment Under Enzyme Replacement in Mice With Mucopolysaccharidosis VII.

Authors:  Takafumi Yamashita; Toshihito Fujii; Ichiro Yamauchi; Yohei Ueda; Keisho Hirota; Yugo Kanai; Akihiro Yasoda; Nobuya Inagaki
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

3.  Supplemented Chondroitin Sulfate and Hyaluronic Acid Suppress Mineralization of the Chondrogenic Cell Line, ATDC5, via Direct Inhibition of Alkaline Phosphatase.

Authors:  Toshiya Kudo; Sachie Nakatani; Misato Kakizaki; Ai Arai; Keisuke Ishida; Masahiro Wada; Kenji Kobata
Journal:  Biol Pharm Bull       Date:  2017       Impact factor: 2.233

4.  Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII.

Authors:  Lachlan J Smith; John T Martin; Spencer E Szczesny; Katherine P Ponder; Mark E Haskins; Dawn M Elliott
Journal:  J Orthop Res       Date:  2010-05       Impact factor: 3.494

5.  Ultrastructural analysis of different skeletal cell types in mucopolysaccharidosis dogs at the onset of postnatal growth.

Authors:  Zhirui Jiang; Yian Khai Lau; Meilun Wu; Margret L Casal; Lachlan J Smith
Journal:  J Anat       Date:  2020-09-07       Impact factor: 2.610

6.  Cell cycle progression is disrupted in murine MPS VII growth plate leading to reduced chondrocyte proliferation and transition to hypertrophy.

Authors:  Zhirui Jiang; Ainslie L K Derrick-Roberts; Clare Reichstein; Sharon Byers
Journal:  Bone       Date:  2019-12-18       Impact factor: 4.398

7.  Clinical course of sly syndrome (mucopolysaccharidosis type VII).

Authors:  Adriana M Montaño; Ngu Lock-Hock; Robert D Steiner; Brett H Graham; Marina Szlago; Robert Greenstein; Mercedes Pineda; Antonio Gonzalez-Meneses; Mahmut Çoker; Dennis Bartholomew; Mark S Sands; Raymond Wang; Roberto Giugliani; Alfons Macaya; Gregory Pastores; Anastasia K Ketko; Fatih Ezgü; Akemi Tanaka; Laila Arash; Michael Beck; Rena E Falk; Kaustuv Bhattacharya; José Franco; Klane K White; Grant A Mitchell; Loreta Cimbalistiene; Max Holtz; William S Sly
Journal:  J Med Genet       Date:  2016-02-23       Impact factor: 6.318

Review 8.  Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.

Authors:  Emma H McCafferty; Lesley J Scott
Journal:  BioDrugs       Date:  2019-04       Impact factor: 5.807

Review 9.  Bone remodelling markers in rheumatoid arthritis.

Authors:  Patrice Fardellone; Alice Séjourné; Julien Paccou; Vincent Goëb
Journal:  Mediators Inflamm       Date:  2014-04-15       Impact factor: 4.711

10.  Bone mineral density in mucopolysaccharidosis IVB.

Authors:  Francyne Kubaski; Heidi H Kecskemethy; H Theodore Harcke; Shunji Tomatsu
Journal:  Mol Genet Metab Rep       Date:  2016-08-08
View more
  3 in total

1.  Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.

Authors:  Yian Khai Lau; Sun H Peck; Toren Arginteanu; Meilun Wu; Megan Lin; Eileen M Shore; Peter S Klein; Margret L Casal; Lachlan J Smith
Journal:  Bone       Date:  2021-10-22       Impact factor: 4.398

Review 2.  Bone Biomarkers in Mucopolysaccharidoses.

Authors:  Akari Nakamura-Utsunomiya
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

Review 3.  MPSI Manifestations and Treatment Outcome: Skeletal Focus.

Authors:  Giada De Ponti; Samantha Donsante; Marta Frigeni; Alice Pievani; Alessandro Corsi; Maria Ester Bernardo; Mara Riminucci; Marta Serafini
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.